177 related articles for article (PubMed ID: 14726142)
1. Stability and transdermal absorption of topical amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Int J Pharm; 2004 Feb; 270(1-2):279-86. PubMed ID: 14726142
[TBL] [Abstract][Full Text] [Related]
2. Characterization of amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Drug Dev Ind Pharm; 2004 May; 30(5):535-43. PubMed ID: 15244089
[TBL] [Abstract][Full Text] [Related]
3. Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B.
Hussain A; Singh VK; Singh OP; Shafaat K; Kumar S; Ahmad FJ
Drug Deliv; 2016 Oct; 23(8):3101-3110. PubMed ID: 27854145
[TBL] [Abstract][Full Text] [Related]
4. Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B.
Hussain A; Samad A; Singh SK; Ahsan MN; Faruk A; Ahmed FJ
Drug Dev Ind Pharm; 2015 May; 41(5):780-90. PubMed ID: 24654936
[TBL] [Abstract][Full Text] [Related]
5. Development of liposomal amphotericin B dry powder inhaler formulation.
Shah SP; Misra A
Drug Deliv; 2004; 11(4):247-53. PubMed ID: 15371106
[TBL] [Abstract][Full Text] [Related]
6. Nanoethosomal formulation for skin targeting of amphotericin B: an in vitro and in vivo assessment.
Kaur L; Jain SK; Manhas RK; Sharma D
J Liposome Res; 2015; 25(4):294-307. PubMed ID: 25547800
[TBL] [Abstract][Full Text] [Related]
7. Stability and release of topical tranexamic acid liposome formulations.
Manosroi A; Podjanasoonthon K; Manosroi J
J Cosmet Sci; 2002; 53(6):375-86. PubMed ID: 12512014
[TBL] [Abstract][Full Text] [Related]
8. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
9. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
10. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
11. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line.
Legrand P; Vertut-Doi A; Bolard J
J Antimicrob Chemother; 1996 Mar; 37(3):519-33. PubMed ID: 9182109
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
Kaur K; Kumar P; Kush P
Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
[TBL] [Abstract][Full Text] [Related]
14. Nanocarrier-based topical drug delivery for an antifungal drug.
Hussain A; Samad A; Nazish I; Ahmed FJ
Drug Dev Ind Pharm; 2014 Apr; 40(4):527-41. PubMed ID: 23627443
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting.
Gupta S; Vyas SP
J Drug Target; 2007 Apr; 15(3):206-17. PubMed ID: 17454358
[TBL] [Abstract][Full Text] [Related]
16. Design of amphotericin B oral formulation for antifungal therapy.
Liu M; Chen M; Yang Z
Drug Deliv; 2017 Nov; 24(1):1-9. PubMed ID: 28155335
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
[TBL] [Abstract][Full Text] [Related]
18. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
19. A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel.
Kang JW; Davaa E; Kim YT; Park JS
J Drug Target; 2010 Sep; 18(8):637-44. PubMed ID: 20192816
[TBL] [Abstract][Full Text] [Related]
20. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
